title: [Pain relief with alendronate therapy in a breast cancer patient with bone metastasis].
abstract: A 66-year-old woman developed a bone metastasis from breast cancer to the sternum in September, 1997. She received alendronate therapy, consisting of biweekly intravenous administrations of 10 mg-alendronate 6 times and monthly 20 mg-alendronate infusions 15 times. The first alendronate administration markedly alleviated her bone pain. She obtained complete pain relief after the 4th alendronate infusion. However, an elevation of tumor marker levels in serum without any pain increase forced us to treat her with medroxyprogesterone acetate and doxifluridine in addition to the alendronate therapy. With these therapies, she has shown an objective response (PR) of the bone metastasis for 8 months. In conclusion, alendronate therapy was effective against bone pain due to metastasis of breast cancer.
authors.affiliation: 1st Dept. of Surgery, Wakayama Medical College.
authors.forename: S
authors.initials: S
authors.lastname: Oura
authors.forename: T
authors.initials: T
authors.lastname: Sakurai
authors.forename: G
authors.initials: G
authors.lastname: Yoshimura
authors.forename: T
authors.initials: T
authors.lastname: Tamaki
authors.forename: T
authors.initials: T
authors.lastname: Umemura
authors.forename: Y
authors.initials: Y
authors.lastname: Kokawa
authors.forename: Y
authors.initials: Y
authors.lastname: Naito
mesh_terms: D000368:Aged; D019386:Alendronate / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D001859:Bone Neoplasms / Q000503:physiopathology* / Q000556:secondary*; D001943:Breast Neoplasms / Q000473:pathology*; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage; D010146:Pain / Q000188:drug therapy*; D013249:Sternum
chemical_list: D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D005467:Floxuridine; D017258:Medroxyprogesterone Acetate; C025034:doxifluridine; D019386:Alendronate